ArticleFrontiers in surgery2026
A novel tubular construct using silk fibroin-chitosan scaffold seeded with bone marrow mesenchymal stem cells for urinary diversion in a preclinical rabbit model.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To construct tissue-engineered tubular grafts (TETGs) using bone marrow mesenchymal stem cells (BMSCs) and silk fibroin/chitosan (SF/CS) scaffolds, and to evaluate their feasibility and efficacy for urinary diversion in a rabbit model. Methods: BMSCs, smooth muscle cells (SMCs), and urothelial cells (UCs) were isolated and characterized Results: BMSCs exhibited high expression of CD44 and CD90 and low expression of CD34 and CD45. BMSCs successfully differentiated into urothelium-like cells, expressing the urothelial-specific proteins uroplakin 1A (UP1A), cytokeratin 7 (CK7), and cytokeratin 13 (CK13). All rabbits in the experimental group survived, showing luminal urothelial growth, with complete epithelialization achieved by week 8. Immunohistochemistry confirmed the presence of mature and functional epithelial cells, as evidenced by positive staining for Anti-cytokeratin AE1/AE3, UP1A, and the tight junction protein ZO-1. IVU confirmed patent outflow tracts without stenosis, urinary fistula, hydronephrosis, or ureteral dilation. In contrast, control grafts collapsed by week 4, resulting in mortality. Conclusion: BMSCs can serve as a viable cell source for urinary tissue engineering. The construction of a urinary diversion conduit using BMSC-derived urothelium-like cells and SF/CS is feasible in rabbits, demonstrating its potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.